logo

Titan Optimax

Bio Active Stent 3rd generation

Titanium Nitride Oxide Effect

Titanium Nitride Oxide is an ACTIVE chemical compound with unique properties whose molecular structure is made of Titanium, Nitrogen and Oxygen.

optimax01


  • Reduces platelet & fibrin deposition (1)
  • Minimizes inflammation (2)


  • Promotes endothelial healing (3)
  • Minimizes thrombus formation (4)


Titanium Nitride Oxide biological effect:

optimax02



Source :
(1) Zhang et al, Journal of Biomedical Material 1998.
(2) Zhang et al, Surface & Coatings Technology 1996.
(3) Hung-I Yeh et al, Journal of Biomedical Material 2006.
(4) Steinemann et al, Injury 1996.


Titanium Nitride Oxide Late Loss

new_optimax03

  • Titanium-Nitride-Oxide is the ONLY Technology lowering Late Loss significantly versus BMS without inducing a risk of Negative Late Loss.
  • Both 1st and 2nd Generation DES with very low Late Loss between 0 and 0.2mm lead to a large proportion of the DES-treated population affected with negative Late Loss (30 to 50%**), territory of delayed healing, AMI, death, Late and Very Late Stent thrombosis thus making compulsory prolonged DAPT.

** Spirit II Trial / EuroIntervention 2006 – Stent thrombosis after implantation of 1st generation DES/Circulation 2007 – Late Lumen Loss pattern after SES implantation/Circulation 2004

Bio Active Stent Biomechanics



o4



Thinner Stent System

  • «Balloon-like» navigability
  •  Expanded crossing capabilities





Advanced Cobalt-Chromium L-605 Platform

  • Higher stent radio-opacity
  • Increased radial force
  • Lower Strut Thickness





2.01F PTFE Coated Hypotube

  • Extra pushability
  • Reduced frictions





New Thinner Tip

  • Excellent trackability
  • Better crossability


Bio Active Stent Efficacy

o8

 


 

 

o10
TiTAN2 demonstrates its non inferiority vs. Xience V in ACS patient in terms of TLR & MACE @12 and 24 months.



Source: BASE-ACS Randomized Trial/EuroPCR 2011 Late Breaking Trials EuroPCR 2012 Scientific Symposium/EuroIntervention 2012

Bio Active Stent Safety

o11

 


 

o12

TiTAN2 demonstrates higher level of safety vs. Xience V @ 12 & 24 months.



Source: BASE-ACS Randomized Trial/EuroPCR 2011 Late Breaking Trials EuroPCR 2012 Scientific Symposium/EuroIntervention 2012

bio active stent healing



OO-13


Source: Base-ACS Randomized Trial


 

  • Low or moderate neointimal hyperplasia
  • Complete endothelialization @18 months
  • No visible thrombus
  • No negative Late Loss
  • Good vascular healing
  • Short DAPT needed



 




OO-14



Source: TiTAX-AMI Randomized Trial


 

  • Low or moderate neointimal hyperplasia
  • Complete endothelialization @36 months
  • No visible thrombus
  • No negative Late Loss
  • Good vascular healing
  • Short DAPT needed

 


Ordering information

o15

 

> <

Products